Cyclin-Dependent Kinases, antagonists & inhibitors
- Name
- Cyclin-Dependent Kinases, antagonists & inhibitors
- Accession Number
- DBCAT001450
- Description
Not Available
- Drugs
Drug Drug Description Olomoucine Not Available Alvocidib Investigated for use/treatment in esophageal cancer, leukemia (lymphoid), lung cancer, liver cancer, and lymphoma (unspecified). OLOMOUCINE II Not Available AT-7519 Investigated for use/treatment in leukemia (unspecified), lymphoma (unspecified), myelodysplastic syndrome, and solid tumors. Palbociclib An endocrine-based chemotherapeutic agent used in combination with other antineoplastic agents to treat HER2-negative and HR-positive advanced or metastatic breast cancer. Dinaciclib Dinaciclib has been used in trials studying the treatment of rrMM, rrCLL, rrDLBCL, Solid Tumors, and Solid Neoplasm, among others. PHA-793887 PHA-793887 has been used in trials studying the treatment of Advanced/Metastatic Solid Tumors. Trilaciclib A CDK4 and CDK6 inhibitor to reduce the risk of chemotherapy induced myelosuppression. Zotiraciclib Zotiraciclib is under investigation in clinical trial NCT02942264 (Zotiraciclib (TG02) Plus Dose-dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in... - Drugs & Drug Targets